Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study
The COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, a...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Impact Journals
2020
|
| _version_ | 1797092439326982144 |
|---|---|
| author | Li, G Liu, Y Jing, X Wang, Y Miao, M Tao, L Zhou, Z Xie, Y Huang, Y Lei, J Gong, G Jin, P Hao, Y Faria, NR Clercq, ED Zhang, M |
| author_facet | Li, G Liu, Y Jing, X Wang, Y Miao, M Tao, L Zhou, Z Xie, Y Huang, Y Lei, J Gong, G Jin, P Hao, Y Faria, NR Clercq, ED Zhang, M |
| author_sort | Li, G |
| collection | OXFORD |
| description | The COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, and North America. Elderly males ≥70 years accounted for only 25% of survivors, but this rate was significantly higher in non-survivors from China (55%), European regions (63%), and North America (47%). Compared with survivors, non-survivors had more incidences of comorbidities such as cerebrovascular disease and chronic obstructive pulmonary disease (COPD, p-values<0.05). Survival analyses revealed age, male gender, shortness of breath, cerebrovascular disease, and COPD as mortality-associated factors. Survival time from symptom onset was significantly shorter in elderly versus young patients (median: 29 versus 62 days), males versus females (median: 46 versus 59 days), and patients with versus without comorbidities (mean: 41 versus 61 days). Mortality risk was higher in elderly males with comorbidities than in young females without comorbidities (p-value<0.01). Elderly male survivors with comorbidities also had longer hospital stays than other survivors (25 versus 18.5 days, p-value<0.01). Overall, the high mortality risk in elderly males with COVID-19-associated comorbidities supports early prevention and critical care for elderly populations. |
| first_indexed | 2024-03-07T03:45:49Z |
| format | Journal article |
| id | oxford-uuid:bf6c4339-0be0-444b-a0ed-6c6787204c50 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:45:49Z |
| publishDate | 2020 |
| publisher | Impact Journals |
| record_format | dspace |
| spelling | oxford-uuid:bf6c4339-0be0-444b-a0ed-6c6787204c502022-03-27T05:47:39ZMortality risk of COVID-19 in elderly males with comorbidities: a multi-country studyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:bf6c4339-0be0-444b-a0ed-6c6787204c50EnglishSymplectic ElementsImpact Journals2020Li, GLiu, YJing, XWang, YMiao, MTao, LZhou, ZXie, YHuang, YLei, JGong, GJin, PHao, YFaria, NRClercq, EDZhang, MThe COVID-19 pandemic causes severe morbidity and mortality. This multi-country study aimed to explore risk factors that drive mortality in COVID-19 patients who received neither dexamethasone nor remdesivir. We analyzed a cohort of 568 survivors and 507 non-survivors from China, European regions, and North America. Elderly males ≥70 years accounted for only 25% of survivors, but this rate was significantly higher in non-survivors from China (55%), European regions (63%), and North America (47%). Compared with survivors, non-survivors had more incidences of comorbidities such as cerebrovascular disease and chronic obstructive pulmonary disease (COPD, p-values<0.05). Survival analyses revealed age, male gender, shortness of breath, cerebrovascular disease, and COPD as mortality-associated factors. Survival time from symptom onset was significantly shorter in elderly versus young patients (median: 29 versus 62 days), males versus females (median: 46 versus 59 days), and patients with versus without comorbidities (mean: 41 versus 61 days). Mortality risk was higher in elderly males with comorbidities than in young females without comorbidities (p-value<0.01). Elderly male survivors with comorbidities also had longer hospital stays than other survivors (25 versus 18.5 days, p-value<0.01). Overall, the high mortality risk in elderly males with COVID-19-associated comorbidities supports early prevention and critical care for elderly populations. |
| spellingShingle | Li, G Liu, Y Jing, X Wang, Y Miao, M Tao, L Zhou, Z Xie, Y Huang, Y Lei, J Gong, G Jin, P Hao, Y Faria, NR Clercq, ED Zhang, M Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study |
| title | Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study |
| title_full | Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study |
| title_fullStr | Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study |
| title_full_unstemmed | Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study |
| title_short | Mortality risk of COVID-19 in elderly males with comorbidities: a multi-country study |
| title_sort | mortality risk of covid 19 in elderly males with comorbidities a multi country study |
| work_keys_str_mv | AT lig mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT liuy mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT jingx mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT wangy mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT miaom mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT taol mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT zhouz mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT xiey mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT huangy mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT leij mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT gongg mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT jinp mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT haoy mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT farianr mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT clercqed mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy AT zhangm mortalityriskofcovid19inelderlymaleswithcomorbiditiesamulticountrystudy |